Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Non-insulin injectable therapy

bs_subtitle

The prevalence of type-2 diabetes is rapidly increasing with up to a quarter of people over 60 years of age affected by it. To reduce the risk of the associated microvascular and macrovascular complications, national guidelines for glycaemic control recommend HbA1c targets of between 6.5€“7·5%. In recent years two novel GLP 1 receptor agonists exenatide and liraglutide have become available for clinical use.

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy